40 patents currently held
12 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2028. from the record
Of the 12 now held by other companies, 12 name Array Biopharma Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
6
Ending by 2030
Aug 2028
Next term end
27
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2039 · High confidence
Also notable
Ends May 2037 · High confidence
Also notable
Ends Feb 2032 · High confidence
Also notable
Ends Nov 2036 · High confidence
Also notable
Ends Nov 2029 · High confidence
Also notable
Ends no later than Sep 2029 · Medium confidence
Also notable
Ends Mar 2041 · High confidence
Also notable
Ends Oct 2040 · High confidence
SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS
US 11,485,738
Cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Kras G12C Inhibitors
US 10,633,381
Cited by 10 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors
US 8,907,091
The most cited patent in this portfolio, cited by 32 later US patents, top 25% of utility patents granted in 2014 in our data. Protection runs to 2032.
LSD1 Inhibitors
US 9,809,541
Cited by 13 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2036.
Fused Heterocycles as Inhibitors of VEGF Receptor and HGF Receptor Signaling
US 8,093,264
Cited by 27 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Inhibitors of Protein Tyrosine Kinase Activity
US 8,404,846
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2029. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
SOS1 Inhibitors
US 11,702,418
Granted 2023. Computed term ends 2041.
MTA-Cooperative PRMT5 Inhibitors
US 11,492,351
Granted 2022. Computed term ends 2040.
Formerly held, still cited
Notable
Ends May 2037 · High confidence
Cited by 35 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
now held by Array Biopharma Inc.
Also notable
Ends May 2037 · High confidence
The most cited patent in this portfolio, cited by 71 later US patents, top 5% of utility patents granted in 2018 in our data. Protection runs to 2037.
now held by Array Biopharma Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 18, 2027The maintenance fee for SOS1 Inhibitors (US 11,702,418) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Apr 17, 2027The maintenance fee for Crystalline Salt of a Multi-Tyrosine Kinase Inhibitor, Method of Preparation, and Use Thereof (US 11,787,819) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 1 fee due Aug 6, 2027The maintenance fee for Combination Therapies (US 11,890,285) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
- 1 fee due Oct 28, 2027The maintenance fee for Kras G12C Inhibitors (US 10,633,381) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
Recent changes
- Nov 16Assignment recorded on 1 record: Keystone Pharma Consulting, LLC to Mirati Therapeutics, Inc. Recorded Nov 16, 2026, executed Nov 3, 2023. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76765, frame 402.
- Nov 16Assignment recorded on 1 record: Macfarlan Smith Limited to Mirati Therapeutics, Inc. Recorded Nov 16, 2026, executed Nov 8, 2023. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76767, frame 41.
- 1 of the patents on this record was granted since Aug 21, 2026
What they patent
The largest of its 27 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | 4 in force | to Jan 2039 |
| Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors | 3 in force | to Feb 2032 |
| Inhibitors of Protein Tyrosine Kinase Activity | 3 in force | to Sep 2029 |
| Adagrasib Solid Pharmaceutical Compositions | 2 in force | to Aug 2043 |
| Crystalline Forms of a Kras G12C Inhibitor | 2 in force | to Apr 2042 |
| Tetrahydropyridopyrimidine Pan-Kras Inhibitors | 2 in force | to Dec 2041 |
| SOS1 Inhibitors | 2 in force | to Mar 2041 |
| MTA-Cooperative PRMT5 Inhibitors | 2 in force | to Oct 2040 |
| LSD1 Inhibitors | 2 in force | to Nov 2036 |
| Azaquinazoline pan-KRas inhibitors | 1 in force | to Apr 2043 |
| Crystalline Form of a Multi-Tyrosine Kinase Inhibitor, Method of Preparation, and Use Thereof | 1 in force | to Jan 2043 |
| Combination Therapies (2021) | 1 in force | to Dec 2042 |
| Naphthyridine Derivatives as PRC2 Inhibitors | 1 in force | to Oct 2042 |
| Combination Therapies (2022) | 1 in force | to Jul 2042 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,389,541 | Inhibitors of Protein Tyrosine Kinase Activity In force · High confidence | In force | High confidence | |
| US 8,569,503 | Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 8,846,927 | Inhibitors of Protein Tyrosine Kinase Activity In force · Medium confidence | In force | Medium confidence | |
| US 9,018,378 | Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 8,404,846 | Inhibitors of Protein Tyrosine Kinase Activity In force · Medium confidence | In force | Medium confidence | |
| US 8,093,264 | Fused Heterocycles as Inhibitors of VEGF Receptor and HGF Receptor Signaling In force · High confidence | In force | High confidence | |
| US 8,907,091 | Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,809,541 | LSD1 Inhibitors In force · High confidence | In force | High confidence | |
| US 10,059,668 | LSD1 Inhibitors In force · High confidence | In force | High confidence | |
| US 10,233,152 | LSD1 Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 40: 12 patents in force now held by others · 1 patent ended · 71 applications pending · 9 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.